In this issue:
- Lisocabtagene maraleucel in CLL/small lymphocytic lymphoma
- Obinutuzumab-ibrutinibvenetoclax for untreated CLL with del(17p)/TP53mut
- Nivolumab + brentuximab vedotin for relapsed/refractory PMBCL
- Immune restoration with first-line ibrutinib + venetoclax in CLL
- Low-dose frontline dasatinib for newly diagnosed chronic-phase CML
- Elranatamab in relapsed/ refractory MM
- More intensive therapy has better effect for frail patients with MM
- Infections following bispecific antibodies in myeloma
- The prognostic impact of t(11;14) in MM
- 5-drug induction and extended consolidation in ultrahigh-risk MM
Please login below to download this issue (PDF)